AbbVie
News on HackerNoon and Around the Web
COMPANY RANKING
#2119
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat...
- Company Ranking
- Stock Price
AbbVie
EVERGREEN INDEX #2119
Related Companies Rank
#2118
AbbVie Story MentionsComplete List
@ikuchma | Mar 09, 2022 | hackernoon.com
Dear Global Economy, Winter is Coming
@ras | Nov 25, 2020 | hackernoon.com
How Buffett Is Hedging Against The Endless Pandemic
@Mappo | May 09, 2019 | hackernoon.com
A Comprehensive List of Enterprises Partnering with blockchain in 2019
@rpair | Aug 13, 2021 | hackernoon.com
Startup Interview with Abbie Shone, Founde and COO of RPAIR
@lmmontgomery | Jul 21, 2023 | hackernoon.com
SHIRLEY GOES
@lmmontgomery | Jul 20, 2023 | hackernoon.com
MARY IS JUST IN TIME
@hacker3798415 | Jun 15, 2023 | hackernoon.com
How The CIA Dissolved Anti-War Activism with LSD 
@valentineenedah | Jan 05, 2023 | hackernoon.com
Memorable Photos from Qatar 2022 FIFA World CupSee more notable links about AbbVie
Apply to get your Tech Company News Page live on HackerNoon.com today!
AbbVie
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.